Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Paranasal sinuses

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Paranasal sinuses. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-003739-22 Sponsor Protocol Number: GAL-01-2007 Start Date*: 2007-10-04
    Sponsor Name:GALSOR S.R.L.
    Full Title: Safety and efficacy (for the symptom remission) of the treatment adjuvant of the antibiotic therapy of the acute episode of sinusitis (acute, subacute, chronic)with Ecballium Elaterium (SINUclean D...
    Medical condition: Acute sinusitis or exacerbation of subacute or chronic sinusitis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040753 Sinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004621-89 Sponsor Protocol Number: LYR-210-2018-002 Start Date*: 2019-07-29
    Sponsor Name:Lyra Therapeutics, Inc.
    Full Title: A Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects with Chronic Sinusitis (LANTERN Study)
    Medical condition: Chronic sinusitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003623-35 Sponsor Protocol Number: CRS-02 Start Date*: 2012-09-14
    Sponsor Name:Bionorica SE
    Full Title: A multicentre, randomized, double-blind, placebo-controlled, parallel group study to assess efficacy and safety of two dosages of a herbal medicinal product (dry extract BNO 1016) in patients with ...
    Medical condition: Chronic Rhinosinusitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) DE (Completed) CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002081-40 Sponsor Protocol Number: Repha_1431 Start Date*: 2017-09-05
    Sponsor Name:Repha GmbH
    Full Title: Investigation of the efficacy and safety of ANGOCIN® Anti-Infekt N versus placebo in adult patients with acute, uncomplicated rhinosinusits. A multi-center, randomized, double-blind, placebo-contro...
    Medical condition: acute uncomplicated rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10052106 Rhinosinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002794-13 Sponsor Protocol Number: ARhiSi-1 Start Date*: 2009-01-28
    Sponsor Name:Bionorica AG
    Full Title: A multi-centre, double-blind, placebo-controlled, randomised, parallel group study to assess the efficacy and safety of two different dosages of a herbal medicinal product (dry extract BNO-1016) in...
    Medical condition: Acute rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052106 Rhinosinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001952-31 Sponsor Protocol Number: CRS-03 Start Date*: 2016-04-14
    Sponsor Name:Bionorica SE
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial to assess efficacy and safety of the herbal medicinal product Sinupret extract coated tablets in patients ...
    Medical condition: Chronic rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10052106 Rhinosinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003117-35 Sponsor Protocol Number: EFC16723 Start Date*: 2021-03-17
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo-controlled, 2-part study to evaluate the efficacy and safety of dupilumab in patients with uncontrolled, chronic rhinosinusitis without nasal polyposis (CRSsNP)
    Medical condition: Chronic rhinosinusitis without nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) SE (Completed) HU (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000907-29 Sponsor Protocol Number: SHDE-1 Start Date*: 2014-08-25
    Sponsor Name:Hevert-Arzneimittel GmbH & Co. KG
    Full Title: Efficacy and safety of Sinusitis Hevert SL tablets compared to placebo in adult patients with acute, uncomplicated rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, paral...
    Medical condition: acute, uncomplicated rhinosinusitis
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-002995-33 Sponsor Protocol Number: MU-707 901 Start Date*: 2007-09-18
    Sponsor Name:MUCOS Pharma GmbH Co. KG
    Full Title: Efficacy and safety of three dosages of Wobenzym mono in patients with acute rhinosinusitis Randomised, comparative, parallell group, placebo controlled, double-blind, multicentre, two phase adapti...
    Medical condition: Acute rhinosinusitis: with a rhinsinusitis symptom score >= 13 points (of maximal 25 points) using a 6 point-rating scala for the following symptoms which arose within up to 3 days prior to visit 1...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052106 Rhinosinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001548-36 Sponsor Protocol Number: pulmozyme-nasal-cf Start Date*: Information not available in EudraCT
    Sponsor Name:University of Jena
    Full Title: Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler. - bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, pr...
    Medical condition: Cystic Fibrosis with chronic rhinosinusitis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002743-41 Sponsor Protocol Number: EA-15-01-996 Start Date*: 2016-11-22
    Sponsor Name:Engelhard Arzneimittel GmbH & Co. KG
    Full Title: Prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center trial to evaluate the efficacy and safety of cineole vs. placebo in the treatment of acute non-purulent rhino...
    Medical condition: Acute, non-purulent rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10052106 Rhinosinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016682-28 Sponsor Protocol Number: ARhiSi-2 Start Date*: Information not available in EudraCT
    Sponsor Name:Bionorica AG
    Full Title: A multi-centre, double-blind, placebo-controlled, randomised, parallel group study to assess the efficacy and safety of a herbal medicinal product (dry extract BNO-1016) in patients with acute rhi...
    Medical condition: Acute rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10052106 Rhinosinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000060-20 Sponsor Protocol Number: 2018-08-EFT-1 Start Date*: 2019-12-20
    Sponsor Name:HEXAL AG
    Full Title: Efficacy and safety of acetylcysteine for the treatment of acute uncomplicated rhinosinusitis: a prospective, randomized, double-blind, placebo-controlled trial
    Medical condition: Acute rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10052106 Rhinosinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-000528-39 Sponsor Protocol Number: TAK-676-1002 Start Date*: 2023-03-20
    Sponsor Name:Takeda Development Center Americas, Inc. (TDC Americas)
    Full Title: An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Ad...
    Medical condition: Solid Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001888-40 Sponsor Protocol Number: DEP NHL-P 001.A Start Date*: 2006-07-24
    Sponsor Name:Mundipharma Research Ltd.
    Full Title: A phase II prospective non-comparative multicenter clinical trial to determine the efficacy and safety of intrathecal liposomal cytarabine (DepoCyte®) in preventing CNS-relapse in patients with agg...
    Medical condition: Prophylaxis of CNS relapse in adult patients with aggressive Non-Hodgkin-Lymphomas at risk for CNS metastasis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10029547 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-006180-36 Sponsor Protocol Number: 22071-24071 Start Date*: 2011-01-18
    Sponsor Name:EORTC - European Organisation for Research and Treatment of Cancer
    Full Title: Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high ris...
    Medical condition: head and neck squamous cell carcinomas (HNSCC) with high risk of locoregional recurrence
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067821 Head and neck cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SI (Completed)
    Trial results: View results
    EudraCT Number: 2021-004627-33 Sponsor Protocol Number: GSN000400 Start Date*: 2022-02-03
    Sponsor Name:Genkyotex Suisse SA
    Full Title: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability, and Effects on Tumour Biomarkers of the NOX1/4 Inhibitor Setanaxi...
    Medical condition: Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003881-96 Sponsor Protocol Number: EPAFC Start Date*: 2016-05-17
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER
    Full Title: Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing classic treatment protocols with classic treatment together with antibiotic treatment o...
    Medical condition: cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003585-11 Sponsor Protocol Number: VX16-659-101 Start Date*: 2017-09-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004479-35 Sponsor Protocol Number: VX16-661-115 Start Date*: Information not available in EudraCT
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Tezacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous or...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) DK (Completed) BE (Completed) DE (Completed) GB (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 07:44:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA